Short communicationRole of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C
Introduction
Chronic hepatitis C (CHC) is a global health problem, related to progressive fibrosis, cirrhosis and end stage liver disease (Thomas and Seeff 2005); some studies examined the role of different factors on the fibrosis progression (Poynard et al. 2001) such as male gender (Poynard et al. 1998), geographical origin (Pearlman 2006), age (Horsmans 2010), insulin resistance and diabetes (Grasso et al. 2009). The fibrosis progression is an important medical reason to encourage the treatment of patients, however in the era of dual therapy with pegylated (PEG)-interferon (IFN) and ribavirin (RBV) not all subjects were eligible to this treatment for the related side-effects, the need of good adherence and other specific conditions as well as older age, psychiatric disorders or risk of anemia (Clark et al., 2012, Roomer et al., 2010, Schaefer et al., 2007). Therefore, a large part of patients affected by CHC were not treated with dual therapy, but the fibrosis progression was different in these subjects (Leandro et al. 2006).
Recently, was observed the role of interleukin (IL) 28B genotype in the spontaneous clearance of HCV infection (Thomas et al. 2009), during antiviral treatment (Suppiah et al. 2009) and as predictive tool used for the optimization of PEG-IFN therapy (Boglione et al., 2015, Boglione et al., 2014); furthermore, the role of IL28B has also been related to fibrosis progression in untreated patients (Bochud et al., 2012, Fabris et al., 2011, Falleti et al., 2011); in details, the GG genotype at rs809917 was associated with a slower progression of fibrosis, while the CC genotype at rs12979860 was related to enhanced immunity and increased necroinflammation (Noureddin et al. 2013).
The aim of this study was to investigate whether the IL28B genotypes (rs12979860 and rs809917) were associated with the liver stiffness variation in a cohort of untreated patients affected by CHC.
Section snippets
Study design
This longitudinal and prospective analysis included all untreated patients followed at our centre of Infectious Disease “Amedeo di Savoia”, Turin, Italy, from 2010 to 2015.
Inclusion criteria were: diagnosis of CHC with positive HCV-RNA, naïve, not eligible for dual therapy or treatment refusal, follow-up of at least 5 years with annual transient elastography evaluation (Fibroscan®).
Genetic evaluation
Genomic DNA was isolated from blood samples. Patients who agreed to undergo genetic analyses and for whom blood
Results
In the study period, 266 patients were considered. The baseline features of the population were reported in the Table 1. Male were 158 (59.3%), with median age of 56 years; most of patients were Italians (66.5%); F1 Metavir score was prevalent (62.4%). The most common HCV genotype was 1b (38.7%). IL28B genotypes (rs8099917 T > G/rs12979860 C > T) were as following: 102 with TT/CC (38.3%), 88 with TT/TC (33%), 40 with TG/TC (15%), and 36 with GG/TT (13.5%). The reasons of delayed treatment with
Discussion
Several studies examined the role of IL28B polymorphisms in the progression of hepatic fibrosis and necroinflammation with different results; although in most cases was reported an association between the rs12979860 CC genotype or rs809917 TT genotype and fibrosis progression (Abe et al., 2010, Bochud et al., 2012), in other studies no relationship was assessed (Marabita et al. 2011) but the heterogeneity of the populations was higher and the method of estimation of fibrosis progression
Conflicts of interest
The authors disclose no conflicts.
Ethical approval
Approved by our local Ethic Committee.
Funding
This study was not supported.
References (26)
- et al.
Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients
J. Hepatol.
(2010) - et al.
Identification of naive HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms
Antivir. Res.
(2014) - et al.
Treatment optimization of naive HCV-1 patients using IL28B, RVR and fibrosis stage
Antivir. Res.
(2015) - et al.
IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC
J. Hepatol.
(2011) - et al.
Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin
J. Hepatol.
(2009) - et al.
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data
Gastroenterology
(2006) - et al.
HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project)
Gastroenterology
(2007) - et al.
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
Lancet
(1998) - et al.
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c
J. Hepatol.
(2001) - et al.
Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy
J. Hepatol.
(2011)
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes
Hepatology
The role of IL28B genotype in HCV-RNA baseline levels
Intervirology
Liver biopsy
N. Engl. J. Med.
Cited by (0)
- 1
Both authors contributed equally to this paper.